North American monoclonal antibodies market is estimated to grow at a CAGR of 6.8% during the forecast period. Some pivotal factors encouraging market growth include a significant rise in cancer incidences and rising new FDA launches for monoclonal antibody drugs. Additionally, launches of monoclonal antibody biosimilars treatment are providing an opportunity for market growth. For instance, in January 2020, Pfizer launched three new biosimilars named rituximab-pvvr (Ruxience), trastuzumab-qyyp (Trazimera), and bevacizumab-bvzr (Zirabev) in the US. This is expected that the specialty drugs will be launched at the lowest wholesale acquisition cost (WAC) among trastuzumab, bevacizumab, or rituximab products currently on the market. These drugs will become available at a discounted price than their equivalents brand name.
Please read the originial post here: https://www.omrglobal.com/industry-reports/north-american-monoclonal-antibodies-market